District Of Columbia § 7-1671.05(Perm) - Medical cannabis program.

Qualifying patients, except qualifying patients enrolled in another jurisdiction's medical cannabis program pursuant to , and the caregivers of qualifying patients; and

Non-resident cardholders;

As part of the registration process, permit a non-resident qualifying patient visiting the District of Columbia to apply to ABCA to receive a temporary non-resident registration identification card, which shall be valid for 30 days; and

After the expiration of a temporary non-resident registration identification card, permit a non-resident qualifying patient to apply to ABCA to be issued another 30-day temporary non-resident identification card.

With respect to registration identification cards issued to persons and entities registered pursuant to paragraph (1)(A) and (C) of this subsection, such cards expire every 2 years:

The cards may be presented to and used by law enforcement to confirm whether a person or entity is authorized to cultivate, manufacture, distribute, dispense, deliver, sell, possess, test, or administer medical cannabis or medical cannabis products, or manufacture, possess, deliver, purchase, sell, distribute, or use paraphernalia; and

The ABC Board may, by rule, establish license and registration periods and fees under the section that are valid for one year, 2 years, or 3 years.

Maintain true, complete, and real-time electronic records of:

Notify ABCA and the Chief of the Metropolitan Police Department in writing and within 24 hours of the loss, theft, or destruction of any medical cannabis;

The medical cannabis has been tested by a testing laboratory;

The cultivation center has received the information required pursuant to paragraph (9) of this subsection; and

The cultivation center has determined that the medical cannabis meets the requirements for sale established by the ABC Board through rulemaking;

The concentration of tetrahydrocannabinol and cannabidiol in the testing material;

Whether the tested material is organic or inorganic;

The presence and concentration of fertilizers or other nutrients;

The presence of mold, mildew, or pests;

Whether the medical cannabis samples contain mycotoxin, pesticides, or heavy metals above a threshold determined by the ABC Board through rulemaking; and

Any other information that the ABC Board may require through rulemaking;

The medical cannabis products have been tested by a testing laboratory;

The manufacturer has received the information required pursuant to paragraph (11) of this subsection; and

The manufacturer has determined that the medical cannabis products meet the requirements for sale established by the ABC Board through rulemaking;

The concentration of tetrahydrocannabinol and cannabidiol in the testing material;

Whether the tested material is organic or inorganic;

The presence and concentration of fertilizers or other nutrients;

Whether the medical cannabis product samples contain mycotoxin or residual solvents above a threshold determined by the ABC Board through rulemaking; and

Any other information that the ABC Board may require through rulemaking;

The potential adverse drug interactions that could occur from using medical cannabis concurrently with other medical treatments;

Harm reduction strategies for qualifying patients who use medical cannabis; and

The importance of informing health care providers and pharmacists of the use of medical cannabis to help avoid adverse drug interactions;

Allows qualifying patients to apply to the ABC Board to be eligible to purchase medical cannabis from retailers and internet retailers at prices set on a sliding scale based upon the qualifying patient's income and existing financial resources; and

Requires each retailer and internet retailer to provide medical cannabis at prices set on the sliding scale described in subparagraph (A) of this paragraph, as determined by the ABC Board, to qualifying patients determined eligible pursuant to subparagraph (A) of this paragraph;

An applicant's knowledge of District and federal law relating to cannabis and rules issued pursuant to ;

A security plan that has been assessed by the Metropolitan Police Department; and

A cultivation plan;

Provide electronic notice to the Councilmember and all Advisory Neighborhood Commissions in the affected ward at least 45 calendar days prior to the approval of a location for a cultivation center, manufacturer, retailer, or internet retailer; and

Accord great weight to input provided by the Advisory Neighborhood Commission regarding the proposed location of a cultivation center, manufacturer, retailer, or internet retailer when approving or rejecting an application for a license;

Establish procedures by which Advisory Neighborhood Commissions can protest new and renewal applications for a cultivation center, manufacturer, retailer, or internet retailer when approving or rejecting an application for a license; and

Establish procedures for an Advisory Neighborhood Commission to enter into a settlement agreement for a cultivation center, manufacturer, retailer, or internet retailer.

The number of qualifying patients participating in the medical cannabis program;

The number of qualifying patients and caregivers registered;

The number of registration identification cards suspended and revoked;

The number of authorized practitioners providing written recommendations for qualifying patients;

The number and location of cultivation centers, manufacturers, retailers, internet retailers, and testing laboratories;

The amount of cannabis harvested by cultivation centers;

The dollar amount of medical cannabis or medical cannabis products sold by cultivation centers, manufacturers, retailers, and internet retailers; and

The number and types of violations of and any applicable rules, taken against licensed cultivation centers, manufacturers, retailers, internet retailers, couriers, and testing laboratories.